Joshua J. Meeks, MD, PhD, discusses data from a real-world study of BCG retreatment after BCG failure in NMIBC.
Joshua J. Meeks, MD, PhD
Advertisement
Articles by Joshua J. Meeks, MD, PhD
Joshua J. Meeks, MD, PhD, discusses effectively implementing recent therapeutic advances across the disease continuum of bladder cancer.
Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the importance of p53 and Rb1 in bladder cancer.
Joshua J. Meeks, MD, PhD, assistant professor of urology, Northwestern University Feinberg School of Medicine, discusses the mutations associated with T1 progression in bladder cancer.
Advertisement
Latest Updated Articles
Dr. Meeks on the Importance of p53 and Rb1 in Bladder CancerJanuary 24th 2019
Advertisement
Advertisement
Trending on OncLive
1
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
2
The OncFive: Top Oncology Articles for the Week of 6/28
3
Luspatercept Sustains Long-Term Transfusion Independence, Favorable OS Trend in ESA-Naive Lower-Risk MDS
4
FDA Grants Breakthrough Device Designation to Merlin CP-GEP for Early-Stage Melanoma Risk Stratification
5